Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial
Ruhlmann, C.H., Christensen, T.B., Hammer Dohn, L., Paludan, M., Roennengart, E., Hilpert, F., Feyer, P., Kristensen, G., Hansen, O., Keefe, D., Herrstedt, J.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article